Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Protein kinase C purification by high-performance liquid chromatography: an improved method

M Go, J Koumoto, U Kikkawa

    Methods in Enzymology
    |January 1, 1987
    PubMed
    Summary

    No abstract available in PubMed .

    Related Experiment Videos

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Cost-effectiveness and safety of the molecular targeted drugs afatinib, gefitinib and erlotinib as first-line treatments for patients with advanced EGFR mutation-positive non-small-cell lung cancer.

    Molecular and clinical oncology·2018
    Same author

    Infection-related complications during treatment for childhood acute lymphoblastic leukemia.

    Annals of oncology : official journal of the European Society for Medical Oncology·2017
    Same author

    Safety of an oral anticancer agent (trifluridine/tipiracil combination tablet) in patients with advanced and recurrent colorectal cancer.

    Die Pharmazie·2016
    Same author

    Preferential Fas-mediated apoptotic execution at G1 phase: the resistance of mitotic cells to the cell death.

    Cell death & disease·2012
    Same author

    The role of IL-33 and its receptor ST2 in human nasal epithelium with allergic rhinitis.

    Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2012
    Same author

    Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphoma.

    Leukemia·2010